Back to Search Start Over

Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits.

Authors :
Kim SH
Kim J
Jang JY
Noh H
Park J
Jeong H
Jeon D
Uhm C
Oh H
Cho K
Jeon Y
On D
Yoon S
Lim SY
Kim SP
Lee YW
Jang HJ
Park IH
Oh J
Seo JS
Kim JJ
Seok SH
Lee YJ
Hong SM
An SH
Kim SY
Kim YB
Hwang JY
Lee HJ
Kim HB
Choi KS
Park JW
Seo JY
Yun JW
Shin JS
Lee HY
Kim K
Lee D
Lee H
Nam KT
Seong JK
Source :
Frontiers in immunology [Front Immunol] 2022 Nov 15; Vol. 13, pp. 1055811. Date of Electronic Publication: 2022 Nov 15 (Print Publication: 2022).
Publication Year :
2022

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a global health concern since 2019. The viral spike protein infects the host by binding to angiotensin-converting enzyme 2 (ACE2) expressed on the cell surface, which is then processed by type II transmembrane serine protease. However, ACE2 does not react to SARS-CoV-2 in inbred wild-type mice, which poses a challenge for preclinical research with animal models, necessitating a human ACE2 (hACE2)-expressing transgenic mouse model. Cytokeratin 18 ( K18 ) promoter-derived hACE2 transgenic mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J] are widely used for research on SARS-CoV-1, MERS-CoV, and SARS-CoV-2. However, SARS-CoV-2 infection is lethal at ≥10 <superscript>5</superscript> PFU and SARS-CoV-2 target cells are limited to type-1 alveolar pneumocytes in K18-hACE2 mice, making this model incompatible with infections in the human lung. Hence, we developed lung-specific SARS-CoV-2 infection mouse models with surfactant protein B ( SFTPB ) and secretoglobin family 1a member 1 ( Scgb1a1 ) promoters. After inoculation of 10 <superscript>5</superscript> PFU of SARS-CoV-2 to the K18-hACE2, SFTPB-hACE2, and SCGB1A1-hACE2 models, the peak viral titer was detected at 2 days post-infection and then gradually decreased. In K18-hACE2 mice, the body temperature decreased by approximately 10°C, body weight decreased by over 20%, and the survival rate was reduced. However, SFTPB-hACE2 and SCGB1A1-hACE2 mice showed minimal clinical signs after infection. The virus targeted type I pneumocytes in K18-hACE2 mice; type II pneumocytes in SFTPB-hACE2 mice; and club, goblet, and ciliated cells in SCGB1A1-hACE2 mice. A time-dependent increase in severe lung lesions was detected in K18-hACE2 mice, whereas mild lesions developed in SFTPB-hACE2 and SCGB1A1-hACE2 mice. Spleen, small intestine, and brain lesions developed in K18-hACE2 mice but not in SFTPB-hACE2 and SCGB1A1-hACE2 mice. These newly developed SFTPB-hACE2 and SCGB1A1-hACE2 mice should prove useful to expand research on hACE2-mediated respiratory viruses.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Kim, Kim, Jang, Noh, Park, Jeong, Jeon, Uhm, Oh, Cho, Jeon, On, Yoon, Lim, Kim, Lee, Jang, Park, Oh, Seo, Kim, Seok, Lee, Hong, An, Kim, Kim, Hwang, Lee, Kim, Choi, Park, Seo, Yun, Shin, Lee, Kim, Lee, Lee, Nam and Seong.)

Details

Language :
English
ISSN :
1664-3224
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
36457995
Full Text :
https://doi.org/10.3389/fimmu.2022.1055811